Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease

por Tseng, Diane, Rachakonda, Leelanand P, Su, Zheng, Advani, Ranjana, Horning, Sandra, Hoppe, Richard T, Quon, Andrew, Graves, Edward E, Loo, Billy W, Tran, Phuoc T
Publicado 2012

A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

por Greenwald, Daniel R, Li, Hailun, Luger, Selina M, Go, Ronald S, King, David, Patel, Taral, Gascoyne, Randy D, Kolesar, Jill, Kahl, Brad S, Horning, Sandra
Publicado 2013

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

por Erbe, Amy K., Wang, Wei, Carmichael, Lakeesha, Hoefges, Anna, Grzywacz, Bartosz, Reville, Patrick K., Ranheim, Erik A., Hank, Jacquelyn A., Kim, KyungMann, Seo, Songwon, Mendonca, Eneida A., Song, Yiqiang, Kenkre, Vaishalee P., Hong, Fangxin, Gascoyne, Randy D., Paietta, Elisabeth, Horning, Sandra J., Miller, Jeffrey S., Kahl, Brad, Sondel, Paul M.
Publicado 2019